Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as a 40 mg injectable solution for intravenous use. It treats acid‑related disorders such as erosive esophagitis, gastro‑oesophageal reflux disease, Zollinger‑Ellison syndrome and helps prevent NSAID‑induced gastric ulcers in adults.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor used to reduce gastric acid secretion in several acid‑related conditions.

- Erosive esophagitis: promotes healing of damaged esophageal lining by decreasing acid exposure. - Gastro‑oesophageal reflux disease (GERD): relieves heartburn and prevents reflux‑related mucosal injury. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors. - Prevention of NSAID‑induced gastric ulcers: reduces risk of ulcer formation in patients receiving non‑steroidal anti‑inflammatory drugs.

Pantoprazole may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhea: loose stools occurring during treatment. - Nausea: occasional feeling of queasiness. - Injection site reactions: pain, erythema, or swelling at the intravenous site.

Serious or Rare Side Effects: - Severe hypersensitivity: rash, angioedema, or anaphylaxis requiring immediate medical attention. - Clostridioides difficile infection: rare cases of severe colitis. - Long‑term use concerns: rare reports of osteoporosis‑related fractures or hypomagnesemia.

When prescribing Pantoprazole injectable solution, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust use in patients with severe kidney dysfunction. - Hepatic impairment: monitor liver function in patients with moderate to severe hepatic disease. - Pregnancy and lactation: category B, use only if benefit outweighs potential risk. - Concomitant use with CYP2C19 substrates: may increase plasma levels of drugs metabolized by this pathway. - Monitoring electrolytes: prolonged therapy can lead to hypomagnesemia; check serum magnesium periodically. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole can affect the pharmacokinetics of other medicines; awareness of key interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Ketoconazole or itraconazole oral formulations: reduced absorption; avoid concurrent use. - Atazanavir: decreased plasma concentration leading to loss of antiviral effect. - Clopidogrel: reduced activation, potentially diminishing antiplatelet activity.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Digoxin: possible increase in serum levels; check digoxin concentrations. - Methotrexate (high dose): may increase toxicity; monitor renal function and drug levels.